Article
Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis

Carlo Augusto Mallio 1,*,†, Andrea Napolitano 2,*,†, Gennaro Castiello 1, Francesco Maria Giordano 1, Pasquale D’Alessio 1, Mario Iozzino 3, Yipeng Sun 4, Silvia Angeletti 5, Marco Russano 2, Daniele Santini 2, Giuseppe Tonini 2, Bruno Beomonte Zobel 1, Bruno Vincenzi 2 and Carlo Cosimo Quattrocchi 1

1 Departmental Faculty of Medicine and Surgery, Unit of Diagnostic Imaging and Interventional Radiology, Università Campus Bio-Medico di Roma, 00128 Rome, Italy; g.castiello@unicampus.it (G.C.); f.giordano@unicampus.it (F.M.G.); p.dalessio@unicampus.it (P.D.); b.zobel@unicampus.it (B.B.Z.); c.quattrocchi@unicampus.it (C.C.Q.)
2 Departmental Faculty of Medicine and Surgery, Unit of Medical Oncology, 00128 Rome, Italy; m.russano@unicampus.it (M.R.); D.Santini@unicampus.it (D.S.); g.tonini@unicampus.it (G.T.); b.vincenzi@unicampus.it (B.V.)
3 Department of Interventional Radiology, S. Maria Goretti Hospital, 04100 Latina, Italy; m.izozino@ausl.latina.it
4 Infervision Europe GmbH, Mainzer Strasse 75, D-65189 Wiesbaden, Germany; syipeng@infervision.com
5 Departmental Faculty of Medicine and Surgery, Unit of Clinical Laboratory Science, Università Campus Bio-Medicodi Roma, 00128 Rome, Italy; S.Angeletti@unicampus.it (B.V.)

* Correspondence: c.mallio@unicampus.it (C.A.M.); a.napolitano@unicampus.it (A.N.); d.santini@unicampus.it (D.S.); t.win@unicampus.it (B.W.); F.M.G.); p.dalessio@unicampus.it (P.D.); b.zobel@unicampus.it (B.B.Z.); c.quattrocchi@unicampus.it (C.C.Q.)
† Authors equally contributed to this manuscript.

Cancers 2021, 13, 652. https://doi.org/10.3390/cancers13040652

Background: Coronavirus disease 2019 (COVID-19) pneumonia and immune checkpoint inhibitor (ICI) therapy-related pneumonitis share common features. The aim of this study was to determine on chest computed tomography (CT) images whether a deep convolutional neural network algorithm is able to solve the challenge of differential diagnosis between COVID-19 pneumonia and ICI therapy-related pneumonitis. Methods: We enrolled three groups: a pneumonia-free group (n = 30), a COVID-19 group (n = 34), and a group of patients with ICI therapy-related pneumonitis (n = 21). Computed tomography images were analyzed with an artificial intelligence (AI) algorithm based on a deep convolutional neural network structure. Statistical analysis included the Mann–Whitney U test (significance threshold at p < 0.05) and the receiver operating characteristic curve (ROC curve). Results: The algorithm showed low specificity in distinguishing COVID-19 pneumonia and ICI therapy-related pneumonitis (sensitivity 97.1%, specificity 14.3%, area under the curve (AUC) = 0.62). Conclusion: The deep learning algorithm is not able to distinguish between COVID-19 pneumonia and ICI therapy-related pneumonitis. Awareness must be increased among clinicians about imaging similarities between COVID-19 and ICI therapy-related pneumonitis. ICI therapy-related pneumonitis can be applied as a challenge population for cross-validation to test the robustness of AI models used to analyze interstitial pneumonias of variable etiology.

Simple Summary: The use of immune checkpoint inhibitors (ICIs) to treat oncologic diseases is progressively increasing. Computed tomography (CT) features of ICI therapy-related pneumonitis may overlap with other diseases, including coronavirus disease 2019 (COVID-19). Thus, oncologic patients undergoing ICI therapy and developing pneumonitis are at risk of being misdiagnosed. Exploring the strengths and weaknesses of artificial intelligence in distinguishing between ICI therapy-related pneumonitis and COVID-19 is of great importance for oncologic patients and for clinicians in order to increase awareness on this topic and stimulate novel strategies aimed to promptly and correctly classify and treat this category of vulnerable patients.
1. Introduction

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus that was first identified in Wuhan, China, and that is responsible for a highly contagious respiratory disease named coronavirus disease 2019 (COVID-19) [1,2]. Due to its rapid global spread, on 11 March 2020, the World Health Organization (WHO) officially characterized COVID-19 as pandemic [3].

Coronaviruses are composed of four major structural proteins, including the envelope (E) protein, the membrane (M) protein, the nucleocapsid (N) protein, and the spike (S) protein, the latter being of paramount importance since it mediates viral attachment to the host cell membrane receptor [4].

Real-time reverse transcription polymerase chain reaction (RT-PCR) and next-generation sequencing methods applied to respiratory tract specimens (e.g., nasopharyngeal or oropharyngeal swab) are considered the reference standard for the diagnosis of SARS-CoV-2 infection [5].

Computed tomography (CT) of the chest can detect lung manifestations, which are often associated with COVID-19 [6–8]. The CT features of COVID-19 pneumonia are nonspecific and may overlap with those of other types of pneumonia and pneumonitis [9], including immune checkpoint inhibitor (ICI) therapy-related pneumonitis.

Recently, the use of ICI therapy as first- and second-line treatment of different types of malignancies has rapidly grown [10]. ICIs act through immune system-mediated destruction of tumor cells [11,12]. ICI therapy-related pneumonitis [13,14] is an uncommon but important immune-related adverse event, with potential significant morbidity and mortality. Importantly, given the expanding population of cancer patients exposed to ICIs, the number of therapy-related pneumonitis is expected to escalate in the near future [15,16]. As the clinical manifestation is often nonspecific, CT plays a critical role in the diagnosis of ICI therapy-related pneumonitis.

Interestingly, COVID-19 pneumonia and ICI therapy-related pneumonitis have been suggested to share critical biological mechanisms, including the hyperactivation of immune cells associated with a significant increase in proinflammatory cytokines [17]. Indeed, for both COVID-19 pneumonia [18] and ICI therapy pneumonitis [19], the use of tocilizumab, a recombinant humanized monoclonal antibody inhibiting the human IL-6 receptor, originally developed for the treatment of rheumatoid arthritis, is under scrutiny [20].

Distinguishing between COVID-19 pneumonia and ICI therapy-related pneumonitis is a diagnostic challenge.

Artificial intelligence (AI), using deep learning technology, is highly promising in the medical imaging field due to its capability of feature extraction and analysis [9,21,22]. It has been also applied to detect various imaging features of chest CT [23,24], allowing qualitative and quantitative analysis, which could provide an estimation of the disease burden, facilitating and expediting imaging interpretation [25,26].

In the present study, given the similar biological and clinical characteristics of COVID-19 pneumonia and ICI therapy-related pneumonitis, we tested whether a deep learning algorithm is able to distinguish between COVID-19 pneumonia and ICI therapy-related pneumonitis.

2. Materials and Methods

We designed a retrospective observational study. This study was performed in accordance with the Declaration of Helsinki. The local Ethical Committee approved the study.
(the ethic code is: Prot.: 88/20 OSS.NOT ComEt CBM) and waived the written informed consent for the participants.

2.1. Participants

All of the subjects underwent chest CT scan and were consecutively sampled from our electronic database. In this study, three groups of patients were included and classified according to both medical history and CT imaging findings (i.e., radiological reports). Inclusion criteria for group selection were as it follows:

COVID-19: a group of consecutive symptomatic (fever > 37.5 °C, dyspnea and/or cough and/or fatigue) patients, with confirmed COVID-19 pneumonia by positive RT-PCR (RealTiMe SARS-CoV-2 Assay, Abbott Laboratories. Abbott Park, IL, USA) on nasopharyngeal (or oropharyngeal) specimen with the swab technique and positive chest CT scans acquired between 15 March and 5 April 2020.

ICI therapy-related pneumonitis: a group of consecutive oncological patients with a positive history of ICI therapy-related pneumonitis and a positive chest CT scan acquired between 2017 and 2019, before the occurrence of any proven case of COVID-19 in Italy. The diagnosis of ICI therapy-related pneumonitis was clinically established based on the absence of other proven microbiological or pharmacological causes of pneumonia, full recovery after drug discontinuation, and medical therapy (mainly based on corticosteroids), and was confirmed by resolution of the findings at follow-up chest CT scan.

Pneumonia-free patients (control group): a group of consecutive symptomatic (fever > 37.5 °C, dyspnea, and/or cough and/or fatigue) patients with a negative chest CT scan acquired between 15 March and 5 April 2020.

2.2. Chest CT Imaging Protocol

All chest CT acquisitions were obtained by maintaining the patients in the supine position during end-inspiration, with or without contrast medium injection. Chest CT images were acquired on a Dual Source 384-slice (2 × 192) CT (Siemens SOMATOM Force, Erlangen, Germany (tube real-time voltage modulation: 70–150 kV; tube real-time dose modulation (CARE Dose4D™) 80–250 mAs; spiral pitch factor: 1.8; collimation width: 0.6 mm)), on a 128-slice CT (Siemens SOMATOM Definition AS, Erlangen, Germany (tube voltage: 120 kV; tube real-time dose modulation (CARE Dose4D™) 80–250 mAs; spiral pitch factor: 1.2; collimation width: 0.6 mm)), and on a 40-slice CT (Philips Brilliance CT (tube voltage: 120 kV; 80–150 mAs; spiral pitch factor: 1.0; collimation width: 0.625 mm)).

A meticulous decontamination of the CT room and passive air exchange was conducted after every scan performed on patients with clinical or imaging suspicion of COVID-19.

2.3. Artificial Intelligence Analysis

The artificial intelligence analysis was performed by means of InferRead™ CT Lung (COVID-19) (Infervision, Europe GmbH, Wiesbaden, Germany), an AI solution specifically developed for diagnosis and management support of COVID-19 pneumonia. Among its features, the algorithm module includes automated segmentation of the core features of COVID-19 lung lesions and the segmentation of the lung lobes (right upper lobe, middle lobe, right lower lobe, left upper lobe, left lower lobe). The output also includes the estimated risk probability for the diagnosis of COVID-19 pneumonia. The core algorithm is based on a deep convolutional neural network structure and uses the U-net network structure as the core segmentation network [27]. The model training process is shown in Figure 1. The cleaned and labeled data are trained through the designated network structure. Continuous testing and parameter adjustments allow for the acquisition of a final model that meets the requirements. The model was developed initially after training on a population of patients diagnosed in Wuhan, China, and was later further developed by training on a larger population. Specifically, for the trained AI model, patients’ characteristics (n = 2191 adult patients; Wuhan Chinese COVID-19) were mixed, including all stages and clinical presentation of the disease (e.g., symptoms could have been mild, moderate,
or severe) [27]. In the Chinese training datasets, controls were 1000 adult patients without COVID-19, who were admitted to Tongji Hospital and had double negative RT-PCR test results. In this group, subjects might or might not have had positive CT findings [27]. The quantitative CT image-derived lesion features analyzed by deep learning model were lung lesion burden volume in terms of cm$^3$ or percentages based on automatic opacity segmentation [27].

Figure 1. Flowchart of the model training process and a diagram to show how the artificial intelligence (AI) model works to generate a prediction risk of disease.

2.4. Statistical Analysis

Descriptive statistics, including means, medians, ranges, and percentiles, were calculated to understand central tendencies of the enrolled cohorts. Data distribution normality was checked by means of Kolmogorov–Smirnov test. The Kruskal–Wallis and the chi-square test were used to compare age and sex distribution among groups, respectively.

This study has three objectives: (1) to assess the AI performance in identifying COVID-19 pneumonia in a population of Italian patients; (2) to test whether the AI could differentiate COVID-19 pneumonia from ICI therapy-related pneumonitis; (3) to test whether the AI could potentially be geared towards the identification and quantitative evaluation of ICI therapy-related pneumonitis.

To investigate the three objectives, we performed the following comparisons: COVID-19 pneumonia vs. pneumonia-free groups, COVID-19 pneumonia vs. ICI therapy-related pneumonitis groups, and ICI therapy-related pneumonitis vs. pneumonia-free groups. COVID-19 disease risk as well as affected lobe percentages and volumes were compared...
between pairs of groups by using the Man–Whitney U test with a significance threshold of \(p < 0.05\). Statistical Package for the Social Sciences (SPSS) software version 26.0 (IBM, Segrate, Milan, Italy) was applied for all the aforementioned statistical computations. Additionally, receiver operating characteristic curve (ROC curve) fitting was performed by using the maximum likelihood fit of a binormal model, and the area under the curve (AUC) was calculated with a 95% confidence interval (95% CI). Sensitivity, specificity, the positive predictive value, and the negative predictive value are presented as point estimates (95% CI).

3. Results

3.1. Study Population Characteristics

Table 1 shows the study population characteristics and the three independent datasets, namely, the pneumonia-free patients \((n = 30)\), patients with COVID-19 pneumonia \((n = 34)\), and patients with ICI therapy-related pneumonitis \((n = 21)\), used to test the AI model.

| Property              | COVID-19   | ICI Therapy-Related | Pneumonia-Free |
|-----------------------|------------|---------------------|-----------------|
| Patients \((n)\)      | 34         | 21                  | 30              |
| Female/male \((n)\)   | 15/19      | 7/14                | 13/17           |
| Age (years)           | 67 (38–87) | 72 (46–82)          | 59 (32–88)      |
| SARS-CoV-2 RT-PCR     | 34/0/0     | 0/0/21              | 0/14/16         |
| Primary cancer        | n/a        | NSCLC \((n = 17)\)  | n/a             |
|                       |            | ccRCC \((n = 1)\)   |                 |
|                       |            | Breast cancer \((n = 1)\) |             |
|                       |            | HCC \((n = 1)\)     |                 |
|                       |            | SCLC \((n = 1)\)    |                 |
| Immunotherapy drug    | n/a        | Nivolumab \((n = 7)\) |               |
|                       |            | Pembrolizumab \((n = 12)\) |        |
|                       |            | Atezolizumab \((n = 2)\) |             |

The number of males was higher than females across all patient groups (pneumonia-free group: 57%; COVID-19 group: 56%; ICI therapy-related pneumonitis: 67%; \(p = 0.70\)). Patients with COVID-19 pneumonia and ICI therapy-related pneumonitis were older than pneumonia-free patients \((p = 0.013)\). The positive SARS-CoV-2 RT-PCR was available for all patients with COVID-19 and a negative RT-PCR test was available for 14/30 (47%) pneumonia-free patients. Within the ICI therapy-related pneumonitis group of patients, non–small-cell lung cancer (NSCLC) was the most prevalent primary tumor (17/21; 81%). The diagnosis of ICI therapy-related pneumonitis occurred as a complication during immunotherapy with nivolumab (7/21; 33%), pembrolizumab (12/21; 57%), and atezolizumab (2/21; 10%). Three patients (3/21; 14%) received concomitant systemic therapy, with paclitaxel, lenvatinib or carboplatin–etoposide, respectively. Six patients (6/21; 29%) were also under long-term prednisolone in doses of 5 mg/day.

3.2. AI Model Performance

The AI processing time for one CT exam was around 10–20 s in a dedicated server with the following configuration characteristics: 16GB RAM, 3TB Drive, GPU-powered Linux server system. The chest CT studies can be automatically forwarded to the AI server located on premises. Once the server receives any study, the AI application starts to process and store the results of AI until the physicians view them. Two series can be analyzed in parallel.
given the number of GPU instances available. The vendor agnostic AI system is capable of analyzing the CT images generated by different CT machine vendors. The system is able to accept CT images generated by CT machines in different reconstruction protocols with a reconstruction slice thickness lower than 1.5 mm. The result can be also accessed with a URL to the case worklist. An instant alert is notified on the case worklist page once the chest CT arrives in the AI server and is deemed as COVID-19 suspicious by the AI application.

The performance of the AI model in terms of risk estimation of COVID-19 pneumonia on chest CT images is summarized in Table 2. When testing the COVID-19 pneumonia vs. pneumonia-free groups, the sensitivity for COVID-19 detection was 97.1% (95% CI: 88.6%, 97.1%), and the specificity was 100% (95% CI: 90.4%, 100%). Differently, when analyzing the COVID-19 pneumonia vs. ICI therapy-related pneumonitis groups, the sensitivity for COVID-19 detection was 97.1% (95% CI: 90.9%, 99.8%), and the specificity was 14.3% (95% CI: 4.3%, 18.8%). Finally, when comparing the ICI therapy-related pneumonitis vs. pneumonia-free groups, the sensitivity for COVID-19 detection was 85.7% (95% CI: 71.3%, 85.7%) with a specificity of 100% (95% CI: 83.2%, 100%).

The ROC curves for the AI risk prediction of COVID-19 pneumonia are shown in Figure 2. The corresponding AUC values for COVID-19 detection depending on the testing dataset are 0.99 (95% CI: 0.98, 1.00) for patients with COVID-19 pneumonia vs. pneumonia-free patients, 0.62 (95% CI: 0.55, 0.70) for patients with COVID-19 pneumonia vs. patients with ICI therapy-related pneumonitis, and 0.97 (95% CI: 0.91, 1.00) for patients with ICI therapy-related pneumonitis vs. pneumonia-free patients, respectively.

![Figure 2](image_url)

**Figure 2.** Receiving operating curves (ROC) of the diagnostic performance of the AI prediction risk of COVID-19 pneumonia. Each plot shows the ROC obtained during testing after including the pairs: COVID-19 and pneumonia-free patients (A), COVID-19 and ICI-related therapy (B) and ICI-related therapy, and pneumonia-free patients (C). Gray lines plot 95% confidence intervals. COVID-19 = coronavirus disease 2019. ICI = immune checkpoint inhibitor. AUC = area under ROC. Std. Error = standard error.

### Table 2. Diagnostic performance of deep learning algorithm across the different group comparisons. Values in parentheses are 95% CI. PPV = positive predictive value, NPV = negative predictive value; Acc = accuracy; AUC = area under the receiving operating curve (ROC). COVID-19 = coronavirus disease 2019. ICI = immune checkpoint inhibitor.

| Group                        | Sensitivity % | Specificity % | PPV %    | NPV %    | Acc % | AUC           |
|------------------------------|---------------|---------------|----------|----------|-------|---------------|
| COVID-19 vs. pneumonia-free  | 97.1 (88.6, 97.1) | 100 (90.4, 100) | 100 (91.2, 100) | 96.8 (87.5, 96.8) | 98.4 | 0.99 (0.98, 1.00) |
| COVID-19 vs. ICI therapy-related | 97.1 (90.9, 99.8) | 14.3 (4.3, 18.8) | 64.7 (60.6, 66.6) | 75.0 (22.6, 98.7) | 60.0 | 0.62 (0.55, 0.70) |
| ICI therapy-related vs. pneumonia-free | 85.7 (71.3, 85.7) | 100 (89.9, 100) | 100 (83.2, 100) | 90.9 (81.7, 90.9) | 94.1 | 0.97 (0.91, 1.00) |
The results of the comparison between COVID-19 pneumonia and ICI therapy-related pneumonitis, in terms of total and lobar involvement, are summarized in Table 3. Considering both the affected lobe percentages and volumes, the left lower lobe appears to be significantly more affected in the COVID-19 group than the ICI therapy-related pneumonitis group ($p < 0.01$).

**Table 3.** Comparison between COVID-19 pneumonia and ICI therapy-related pneumonia based on total and lobar involvement. Volumes are reported as median values of the relative percentage of lobar involvement and absolute volumes. Values in parentheses are 25% and 75% percentiles that were used instead of minimum and maximum, as the value of 0 was frequent in the distribution. ICI = immune checkpoint inhibitor, COVID-19 = coronavirus disease 2019. RUL = right upper lobe, ML = middle lobe, RLL = right lower lobe, LUL = left upper lobe; LLL, left lower lobe.

|                  | ICI Therapy (%) | COVID-19 (%) | ICI Therapy-Related (%) | $p$-Value |
|------------------|-----------------|--------------|-------------------------|-----------|
| TOTAL (cm$^3$)   | 2.95 (1.22–8.89)| 1.68 (0.28–9.62) | 52.03 (6.95–225.0) | 0.27      |
| RUL (%)          | 0.78 (0.15–5.12) | 0.17 (0–10.84) | 1.92 (0–14.22) | 0.43      |
| ML (%)           | 0.24 (0–3.89)   | 0.28 (0–3.47) | 1.00 (0–13.58) | 0.66      |
| RLL (%)          | 3.54 (1.19–11.06)| 1.48 (0.02–11.80) | 4.83 (0–41.02) | 0.09      |
| LUL (%)          | 0.73 (0.05–5.70) | 0 (0–2.81) | 0 (0–15.42) | 0.10      |
| LLL (%)          | 3.99 (0.46–17.56) | 0 (0–2.10) | 0 (0–10.97) | <0.01     |
| COVID-19 RISK (%)| 41.85 (34.52–51.12) | 34.4 (27.2–46.4) |                      | 0.16      |

Representative CT images are shown in Figure 3.
4. Discussion

In this study, we assessed the performance of a deep learning algorithm, initially trained on a population of Wuhan in China, in solving the challenge of differential diagnosis between COVID-19 pneumonia and ICI therapy-related pneumonitis.
The patients with RT-PCR confirmed diagnosis of COVID-19 pneumonia, showing the typical CT findings reported in several studies [6,7,28–31]. The most relevant CT features were multifocal and peripheral (and often bilateral) ground-glass areas associated with subsegmental patchy consolidations, with predominant involvement of the lower lung lobes. As expected, we found excellent accuracy of the algorithm in the detection of COVID-19 pneumonia when compared with pneumonia-free patients (AUC = 0.99). These results support the use of the algorithm as a valid tool for diagnosis and management support of COVID-19 pneumonia in the Italian population, similarly to what was reported in the Chinese population [9], especially in those settings where the automated analysis could be used to rapidly screen patients admitted with symptoms of suspect COVID-19 pneumonia. In this context, based also on the pathological autopic findings, it should be underlined that the known coexistence of viral and bacterial infections in COVID-19 patients hinders the binary approach used by AI algorithms in the classification of bacterial vs. viral pneumonia or COVID-19 vs. non COVID-19 pneumonia. In real clinical settings, lung consolidations can be the results of more complex clinical patterns, especially in the later stages of disease [32].

ICI therapy-related pneumonitis is an uncommon but important complication of ICI therapy. Since the clinical manifestations of ICI therapy-related pneumonitis are nonspecific, CT plays an important role in the diagnosis of this adverse event. ICI therapy-related pneumonitis might present with several patterns that include organizing pneumonia, nonspecific interstitial pneumonia, and acute interstitial pneumonia–acute respiratory distress syndrome [10]. These patterns seemingly overlap the CT features of COVID-19 pneumonia possibly due to overlapped biological mechanisms. Here, we indeed show that ICI therapy-related pneumonitis was classified by the AI algorithm as COVID-19 pneumonia (AUC = 0.62). These results emphasize the exceptional diagnostic challenge represented by interstitial lung disease in patients with cancer who undergo ICI therapy during the epidemic of COVID-19. Surprisingly, the analysis of lobar involvement showed that the left lower lobe was significantly more affected in COVID-19 patients compared to those with ICI therapy-related pneumonitis. Since ICI therapy-related pneumonitis has been reported to frequently affect the lower lobes [33], the result of the left lower lobe reported in the present study might be influenced by the small sample size. Nevertheless, it should be further investigated in larger cohorts, as it might hint to biological and pathogenic peculiarities of COVID-19 pneumonia with respect to ICI therapy-related pneumonitis.

Given the capability of the COVID-19 algorithm to capture features shared between COVID-19 pneumonia and ICI therapy-related pneumonitis, we were able to show an excellent accuracy of the AI in distinguishing ICI therapy-related pneumonitis from pneumonia-free cases (AUC = 0.97). The result suggests that the algorithm might be geared towards the identification and quantitative evaluation of lungs affected by ICI therapy-related pneumonitis. This interesting hypothesis needs to be further verified with a larger CT dataset of ICI therapy-related pneumonitis, also given the limited sample size of the present study. Additionally, a “transfer learning” strategy, including some ICI patients’ CT data, should be tested and adapted for the partial training of algorithms. This is particularly important, as COVID-19 pneumonia cases are expected to decrease in the future and might become epidemiologically less relevant with the development and distribution of adequate vaccination therapies, whereas the number of ICI therapy-related pneumonitis is predicted to increase according to the increasing usage of ICI in cancer patients [34].

This study has several limitations, including the small size of the samples and the variability of protocols used with the three different scanners. Other viral or bacterial pneumonias were not included in this study; thus, we cannot estimate the accuracy of the AI algorithm for the differential diagnosis with other infectious pneumonias. Moreover, the overlapping chest CT features of several diseases reflect common mechanisms of response of the lungs to different etiologies; therefore, measurements of volume, shape, or density of pulmonary lesions may not be sufficient features to develop powerful deep
learning models. Lesion distribution and other radiomics-based data, including clinical information, are promising to further improve the performance of AI algorithms [35].

5. Conclusions

In conclusion, the AI model, initially developed on the population of Wuhan, classified ICI therapy-related pneumonitis as COVID-19 pneumonias due to shared features between the two conditions, and it distinguished ICI therapy-related pneumonitis from pneumonia-free controls. Awareness must be increased among clinicians about imaging similarities between COVID-19 and ICI therapy-related pneumonitis. ICI therapy-related pneumonitis can be applied as a challenge population for cross-validation to test the robustness of the AI models used to analyze interstitial pneumonias of variable etiology.

Author Contributions: C.A.M., A.N., B.V., and C.C.Q. are responsible for study conception and design; C.A.M. is responsible for data acquisition; C.A.M., Y.S., D.S., G.T., B.B.Z., and B.V. drafted the article; C.A.M., A.N., G.C., F.M.G., P.D., M.I., S.A., M.R., D.S., G.T., B.B.Z., and B.V. analyzed and interpreted data. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was performed in accordance with the Declaration of Helsinki. The local Ethical Committee approved the study and waived the written informed consent for the participants.

Informed Consent Statement: The local Ethical Committee waived the written informed consent for publication.

Data Availability Statement: Data are available upon request to the corresponding author.

Acknowledgments: The authors are thankful to Wen Tang for the help in revising the manuscript.

Conflicts of Interest: Y.S. currently works for Infervision Europe GmbH, where artificial intelligence tools for clinical use are developed. To date, Infervision’s machines are pending FDA approval. All the other authors of this manuscript have no potential conflicts of interest and/or financial support, regardless of whether directly related to the subject of this paper or not.

Abbreviations

SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
COVID-19 coronavirus disease 2019
WHO World Health Organization
RT-PCR real-time reverse transcription polymerase chain reaction
CT computed tomography
ICI immune checkpoint inhibitors
AI artificial intelligence
ROC receiver operating characteristic
AUC area under the curve
SPSS Statistical Package for the Social Sciences

References

1. Fauci, A.S.; Lane, H.C.; Redfield, R.R. Covid-19 Navigating the Uncharted. N. Engl. J. Med. 2020, 382, 1268–1269. [CrossRef]
2. Gorbalenya, A.E.; Baker, S.C.; Baric, R.S.; de Groot, R.J.; Drosten, C.; Gulyaeva, A.A.; Haagmans, B.L.; Lauber, C.; Leontovich, A.M.; Neuman, B.W.; et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses—A statement of the Coronavirus Study Group. BioRxiv 2020. [CrossRef]
3. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 2020 09/04/2020. Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed on 1 November 2020).
4. Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol. 2015, 1282, 1–23. [PubMed]
5. CDC. Coronavirus Disease 2019 (COVID-19) 2020 10/04/2020. Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html (accessed on 1 November 2020).
6. Chung, M.; Bernheim, A.; Mei, X.; Zhang, N.; Huang, M.; Zeng, X.; Cui, J.; Xu, W.; Yang, Y.; Fayad, Z.A.; et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). *Radiology* 2020, 295, 202–207. [CrossRef]

7. Caruso, D.; Zerunian, M.; Polici, M.; Pucciarelli, F.; Polidori, T.;ucci, G.; Guido, G.; Bracci, B.; De Dominicis, C.; Laghi, A. Chest CT Features of COVID-19 in Rome. *Italy. Radiology* 2020, 296, E79–E85. [CrossRef] [PubMed]

8. Rubin, G.D.; Ryerson, C.J.; Haramati, L.B.; Sverzellati, N.; Kanne, J.P.; Raoof, S.; Schlager, N.W.; Volpi, A.; Yim, J.-J.; Martin, I.B.K.; et al. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology* 2020, 296, 172–180. [CrossRef] [PubMed]

9. Li, L.; Qin, L.; Xu, Z.; Yin, Y.; Wang, X.; Kong, B.; Bai, J.; Lu, Y.; Fang, Z.; Song, Q.; et al. Artificial Intelligence Distiguishes COVID-19 from Community Acquired Pneumonia on Chest CT. *Radiology* 2020, 209005. [CrossRef]

10. Kalisz, K.R.; Ramaiya, N.H.; Laukamp, K.R.; Gupta, A. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. *Radiographics* 2019, 39, 1923–1937. [CrossRef] [PubMed]

11. Granier, C.; De Guillebon, E.; Blanc, C.; Roussel, H.; Badoual, C.; Colin, E.; Saldmann, A.; Klearman, M.; Musselman, D.; Agarwal, S.; et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. *J. Clin. Oncol.* 2016, 34, 1607–1616. [CrossRef] [PubMed]

12. Martinez-Lostao, L.; Anel, A.; Pardo, J. How Do Cytotoxic Lymphocytes Kill Cancer Cells? *Clin. Cancer Res.* 2015, 21, 5047–5056. [CrossRef]

13. Naidoo, J.; Wang, X.; Woo, K.M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J.E.; Segal, N.H.; Callahan, M.K.; Lesokhin, A.M.; et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. *J. Clin. Oncol.* 2017, 35, 709–717. [CrossRef] [PubMed]

14. Nishino, M.; Giobbie-Hurder, A.; Hatabu, H.; Ramaiya, N.H.; Hodi, F.S. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis and Management. *Radiographics* 2019, 39, 1923–1937. [CrossRef] [PubMed]

15. Kaehler, K.C.; Piel, S.; Livingstone, E.; Schilling, B.; Hauschild, A.; Schadendorf, D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management. *Semin Oncol.* 2010, 37, 485–498. [CrossRef]

16. Stucci, S.; Palmirotta, R.; Passarelli, A.; Silvestris, E.; Argentiero, A.; Lanotte, L.; Acquafredda, S.; Todisco, A.; Silvestris, F. Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management. *Oncl. Lett.* 2017, 14, 5671–5680. [CrossRef]

17. Bersanelli, M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. *Immunotherapy* 2020, 12, 269–273. [CrossRef]

18. Di Giambenedetto, S.; Siccullo, A.; Borghetti, A.; Gambassi, G.; Landi, F.; Visconti, E.; Dal Verme, L.Z.; Bernabei, R.; Tamburrini, E.; Cauda, R.; et al. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection. *J. Med. Virol.* 2020, 92, 1787–1788. [CrossRef]

19. Stroud, C.R.; Hegde, A.; Cherry, C.; Naqash, A.R.; Sharma, N.; Addepalli, S.; Cherukuri, S.; Parent, T.; Hardin, J.; Walker, P. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. *J. Oncol. Pharm. Pract.* 2019, 25, 551–557. [CrossRef]

20. Gabay, C.; Emery, P.; van Vollenhoven, R.; Dikranian, A.; Alten, R.; Pavelka, K.; Klearman, M.; Musselman, D.; Agarwal, S.; Green, J.; et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. *Lancet* 2013, 381, 1541–1550. [CrossRef]

21. Ronneberger, O.; Fischer, P.; Brox, T. U-Net: Convolutional Networks for Biomedical Image Segmentation. In *Medical Image Computing and Computer-Assisted Intervention—MICCAI*, Lecture Notes in Computer Science; Navab, N., Hornegger, J., Wels, W., Frangi, A., Eds.; Springer: Cham, Switzerland, 2015; p. 9351.

22. Kermany, D.S.; Goldbaum, M.; Cai, W.; Valentin, C.C.S.; Liang, H.; Baxter, S.L.; McKeown, A.; Yang, G.; Wu, X.; Yan, F.; et al. Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning. *Cell* 2018, 172, 1122–1131.e9. [CrossRef]

23. Depeursinge, A.; Chin, A.S.; Leung, A.N.; Terrone, D.; Bristow, M.; Rosen, G.; Rubin, D.L. Automated classification of usual interstitial pneumonia using regional volumetric texture analysis in high-resolution computed tomography. *Invest. Radiol.* 2015, 50, 261–267. [CrossRef]

24. Anthimopoulos, M.; Christodoulidis, S.; Ebner, L.; Christie, A.; Mougiakakou, S. Lung Pattern Classification for Interstitial Lung Diseases Using a Deep Convolutional Neural Network. *IEEE Trans. Med. Imaging* 2016, 35, 1207–1216. [CrossRef] [PubMed]

25. Huang, L.; Han, R.; Ai, T.; Yu, P.; Kang, H.; Tao, Q.; Xia, L. Serial Quantitative Chest CT Assessment of COVID-19: Deep-Learning Analysis of Lesion Burden for COVID-19: A retrospective study with external validation. *Lancet Digit. Health* 2020, 10, e506–e515. [CrossRef]
28. Simpson, S.; Kay, F.U.; Abbara, S.; Bhalla, S.; Chung, J.H.; Chung, M.; Henry, T.S.; Kanne, J.P.; Kligerman, S.; Ko, J.P.; et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. *J. Thorac. Imaging* 2020. [CrossRef]

29. Yang, R.; Li, X.; Liu, H.; Zhen, Y.; Zhang, X.; Xiong, Q.; Luo, Y.; Gao, C.; Zeng, W. Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19. *Radiol. Cardiothorac. Imaging* 2020, 2, e200047. [CrossRef]

30. Choi, H.; Qi, X.; Yoon, S.H.; Park, S.J.; Lee, K.H.; Kim, J.Y.; Lee, Y.K.; Ko, H.; Kim, K.H.; Park, C.M.; et al. Extension of Coronavirus Disease 2019 (COVID-19) on Chest CT and Implications for Chest Radiograph Interpretation. *Radiol. Cardiothorac. Imaging* 2020, 2, e204001. [CrossRef]

31. Wang, Y.; Dong, C.; Hu, Y.; Li, C.; Ren, Q.; Zhang, X.; Shi, H.; Zhou, M. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology* 2020, 296, E55–E64. [CrossRef]

32. Hanley, B.; Lucas, S.B.; Youd, E.; Swift, B.; Osborn, M. Autopsy in suspected COVID-19 cases. *J. Clin. Pathol.* 2020, 73, 239–242. [CrossRef]

33. Porcu, M.; De Silva, P.; Solinas, C.; Battaglia, A.; Schena, M.; Scartozi, M.; Bron, D.; Suri, J.S.; Willard-Gallo, K.; Sangiolo, D.; et al. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. *Cancers* 2019, 11, 305. [CrossRef]

34. Russano, M.; Citarella, F.; Napolitano, A.; Dell’Aquila, E.; Cortellini, A.; Pantano, F.; Vencenzi, B.; Tonini, G.; Santini, D. COVID-19 pneumonia and immune-related pneumonitis: Critical issues on differential diagnosis, potential interactions, and management. *Expert Opin. Biol. Ther.* 2020, 20, 959–964. [CrossRef] [PubMed]

35. Mallio, C.A.; Quattrocchi, C.C.; Zobel, B.B.; Parizel, P.M. Artificial intelligence, chest radiographs, and radiology trainees: A powerful combination to enhance the future of radiologists? *Quant. Imaging Med. Surg.* 2021. [CrossRef]